IL166401A0 - Pharmaceutical compositions containing endothelialer - Google Patents

Pharmaceutical compositions containing endothelialer

Info

Publication number: IL166401A0
Authority: IL; Israel
Prior art keywords: epo; tissue; endothelial; derivatives; stimulating
Prior art date: 2002-07-26

Application number

IL16640105A

Other languages

English (en)

Original Assignee

Epoplus Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-26

Filing date

2005-01-20

Publication date

2006-01-15

2005-01-20 Application filed by Epoplus Gmbh & Co Kg filed Critical Epoplus Gmbh & Co Kg

2006-01-15 Publication of IL166401A0 publication Critical patent/IL166401A0/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
210000002889 endothelial cell Anatomy 0.000 abstract 4
210000000056 organ Anatomy 0.000 abstract 3
230000015572 biosynthetic process Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000003511 endothelial effect Effects 0.000 abstract 2
230000004936 stimulating effect Effects 0.000 abstract 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
102100035194 Placenta growth factor Human genes 0.000 abstract 1
229940123934 Reductase inhibitor Drugs 0.000 abstract 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
WGUYYUOFQYVTLR-BLPRJPCASA-N [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO Chemical compound [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO WGUYYUOFQYVTLR-BLPRJPCASA-N 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002402 anti-lipaemic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
210000004204 blood vessel Anatomy 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
210000003709 heart valve Anatomy 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000005012 migration Effects 0.000 abstract 1
238000013508 migration Methods 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
230000004862 vasculogenesis Effects 0.000 abstract 1
230000000982 vasogenic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL16640105A 2002-07-26 2005-01-20 Pharmaceutical compositions containing endothelialer IL166401A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10234192A DE10234192B4 (de)	2002-07-26	2002-07-26	Verwendung von Erythropoetin
PCT/EP2003/008229 WO2004012759A2 (de)	2002-07-26	2003-07-25	Erythropoetin zur stimulation endothelialer voläuferzellen

Publications (1)

Publication Number	Publication Date
IL166401A0 true IL166401A0 (en)	2006-01-15

Family

ID=30128436

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16640105A IL166401A0 (en)	2002-07-26	2005-01-20	Pharmaceutical compositions containing endothelialer
IL204577A IL204577A (en)	2002-07-26	2010-03-18	Pharmaceutical compositions containing erythropoietin for the treatment of diabetes mellitus

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL204577A IL204577A (en)	2002-07-26	2010-03-18	Pharmaceutical compositions containing erythropoietin for the treatment of diabetes mellitus

Country Status (26)

Country	Link
US (4)	US7745387B2 (pl)
EP (3)	EP2191838A1 (pl)
JP (4)	JP4727988B2 (pl)
KR (2)	KR20100077033A (pl)
CN (3)	CN101099731B (pl)
AT (2)	ATE360436T1 (pl)
AU (2)	AU2003255290B2 (pl)
BR (1)	BR0312981A (pl)
CA (2)	CA2710100A1 (pl)
CY (2)	CY1108052T1 (pl)
DE (3)	DE10234192B4 (pl)
DK (2)	DK1526867T3 (pl)
EA (3)	EA200801236A1 (pl)
ES (2)	ES2345673T3 (pl)
HR (3)	HRP20070189A2 (pl)
IL (2)	IL166401A0 (pl)
IS (3)	IS2671B (pl)
MX (1)	MXPA05001120A (pl)
NO (1)	NO20051002L (pl)
PL (2)	PL395151A1 (pl)
PT (2)	PT1526867E (pl)
SG (1)	SG177004A1 (pl)
SI (2)	SI1779862T1 (pl)
UA (2)	UA85997C2 (pl)
WO (1)	WO2004012759A2 (pl)
ZA (1)	ZA200500726B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723303B2 (en)	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) *	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
WO2005014023A1 (en) *	2003-07-29	2005-02-17	Dompe' Pha.R.Ma S.P.A.	Pharmaceutical combination of g-csf and plgf useful for blood stem cell
DK1699915T3 (da) *	2003-12-30	2010-09-13	Augustinus Bader	Anvendelse af erythropoietin til levervævsregenerering
DE102004063927A1 (de) *	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7579319B2 (en)	2004-12-06	2009-08-25	The Regents Of The University Of California	Methods for improving the structure and function of arterioles
AR053416A1 (es)	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP2781222B1 (en)	2005-11-23	2017-08-02	Acceleron Pharma, Inc.	Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
AU2007255717B2 (en) *	2006-06-07	2013-07-11	Chugai Seiyaku Kabushiki Kaisha	Treatment of ischemic disease using erythropoietin
EP2109456A2 (en) *	2006-09-29	2009-10-21	Centocor Ortho Biotech Inc.	Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions
EP2078731A4 (en) *	2006-10-20	2012-08-01	Forerunner Pharma Res Co Ltd	ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE
US8975374B2 (en) *	2006-10-20	2015-03-10	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008047914A1 (fr)	2006-10-20	2008-04-24	Forerunner Pharma Research Co., Ltd.	Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101610782A (zh) *	2007-01-10	2009-12-23	爱迪生药物公司	使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
AR065613A1 (es) *	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
WO2009022338A2 (en)	2007-08-16	2009-02-19	Saher Hamed	Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
CA2724841A1 (en) *	2008-05-22	2009-11-26	Edison Pharmaceuticals, Inc.	Treatment of mitochondrial diseases with an erythropoietin mimetic
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja)	2009-06-08	2016-04-27	アクセルロンファーマ，インコーポレイテッド	熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en)	2009-06-12	2020-09-02	Acceleron Pharma Inc.	Truncated actriib-fc fusion proteins
CN102655872B (zh) *	2009-08-13	2016-01-20	阿塞勒隆制药公司	Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
EP3332796A1 (en)	2009-11-17	2018-06-13	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
ES2632164T3 (es)	2010-07-06	2017-09-11	Augustinus Bader	Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
WO2012148200A2 (ko) *	2011-04-26	2012-11-01	아주대학교 산학협력단	허혈성 혈관 질환 치료시술 보조용 조성물
US10195249B2 (en)	2012-11-02	2019-02-05	Celgene Corporation	Activin-ActRII antagonists and uses for treating bone and other disorders
US8992951B2 (en)	2013-01-09	2015-03-31	Sapna Life Sciences Corporation	Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
EP3060174B1 (en) *	2013-10-22	2020-05-27	Concievalve LLC	Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
MA40008A (fr)	2014-06-13	2021-05-05	Acceleron Pharma Inc	Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
WO2016131052A1 (en)	2015-02-13	2016-08-18	Factor Bioscience Inc.	Nucleic acid products and methods of administration thereof
CN105233256A (zh) *	2015-10-28	2016-01-13	中国人民解放军第三军医大学	促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) *	2016-03-09	2022-12-27	Aal Scientifics, Inc.	Pancreatic stem cells and uses thereof
GB2550114A (en) *	2016-05-03	2017-11-15	Kymab Ltd	Methods, regimens, combinations & antagonists
IL308824A (en)	2016-08-17	2024-01-01	Factor Bioscience Inc	Nucleic acid products and methods of administration thereof
CN108114282B (zh) *	2016-11-28	2021-03-02	北京大学第三医院	他汀类化合物治疗缺血性疾病的用途
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en)	2017-10-20	2023-07-04	Hyogo College Of Medicine	Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja)	2018-01-31	2019-08-08	元一加藤	Ｉｌ－６阻害剤を含有する喘息の治療剤
RU2695334C1 (ru) *	2018-09-25	2019-07-23	Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ")	Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
RU2678768C1 (ru) *	2018-09-25	2019-02-01	Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ")	Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
WO2020213665A1 (ja)	2019-04-17	2020-10-22	国立大学法人広島大学	Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
JP7699552B2 (ja)	2019-07-03	2025-06-27	ファクターバイオサイエンスインコーポレイテッド	カチオン性脂質及びその使用
US10501404B1 (en)	2019-07-30	2019-12-10	Factor Bioscience Inc.	Cationic lipids and transfection methods
JP2023544727A (ja)	2020-10-02	2023-10-25	ケロスセラピューティクスインコーポレイテッド	アクチビン受容体ｉｉ型バリアントの使用方法
CN119080909A (zh) *	2024-08-29	2024-12-06	深圳赛保尔生物药业有限公司	负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4732889A (en)	1985-02-06	1988-03-22	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3686582T2 (de)	1985-11-27	1993-01-28	Genetics Inst	Behandlung einer krankheit vom aids-typ.
US5198417A (en) *	1985-11-27	1993-03-30	Genetics Institute, Inc.	Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
DK173067B1 (da)	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en)	1986-11-21	1991-05-07	Amgen, Inc.	Method for treating iron overload using EPO
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
AU4072189A (en) *	1988-02-24	1989-09-22	American National Red Cross, The	Device for site directed neovascularization and method for same
US5024841A (en) *	1988-06-30	1991-06-18	Collagen Corporation	Collagen wound healing matrices and process for their production
DE4014654A1 (de)	1990-05-08	1991-11-14	Behringwerke Ag	Galenische waessrige formulierungen von erythropoietin und ihre verwendung
AU660019B2 (en) *	1991-03-11	1995-06-08	Stryker Corporation	Protein-induced morphogenesis
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
CN1125401A (zh)	1993-04-29	1996-06-26	艾博特公司	促红细胞生成素类似物组合物和方法
IL192290A0 (en)	1993-08-17	2008-12-29	Kirin Amgen Inc	Erythropoietin analogs
JPH08205860A (ja) *	1994-01-21	1996-08-13	Usa Government	造血細胞の膨大化および移植方法
ITFI940106A1 (it) *	1994-05-27	1995-11-27	Menarini Ricerche Sud Spa	Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
ES2206521T3 (es)	1994-11-03	2004-05-16	Roche Diagnostics Gmbh	Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide.
US5837675A (en) *	1995-02-03	1998-11-17	Brox; Alan G.	Synergistic effect of insulin-like growth factor-I and erythropoietin
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
US5980887A (en) *	1996-11-08	1999-11-09	St. Elizabeth's Medical Center Of Boston	Methods for enhancing angiogenesis with endothelial progenitor cells
US6284260B1 (en)	1998-02-04	2001-09-04	Veronica L. Zaharia Czeizler	Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
US6274158B1 (en) *	1998-02-04	2001-08-14	Veronica L. Zaharia Czeizler	Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CA2383940A1 (en) *	1999-04-13	2000-10-19	The Kenneth S. Warren Laboratories, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
NZ522851A (en)	2000-05-02	2004-11-26	Action Pharma Aps	Treatment of inflammatory diseases associated with neutrophil or eosinophil granulocyt inflitration with EPO optionally with alpha-MSH
US7259146B2 (en) *	2000-05-26	2007-08-21	Ortho-Mcneil Pharmaceutical, Inc.	Neuroprotective peptides
US7078376B1 (en)	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) *	2000-11-29	2002-05-30	Adrian Iaina	Method of treating congestive heart failure
PA8536201A1 (es)	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
WO2002085940A2 (en) *	2001-04-04	2002-10-31	Genodyssee	New polynucleotides and polypeptides of the erythropoietin gene
US6784154B2 (en) *	2001-11-01	2004-08-31	University Of Utah Research Foundation	Method of use of erythropoietin to treat ischemic acute renal failure
US7232797B2 (en) *	2001-11-28	2007-06-19	Ortho-Mcneil Pharmaceutical, Inc.	Erythropoietin dosing regimen for treating anemia
CA2476538C (en)	2002-01-09	2012-07-17	Crucell Holland B.V.	Use of erythropoietin for the preventive or curative treatment of cardiac failure
US6748154B2 (en) *	2002-03-28	2004-06-08	Nortel Networks Limited	Optical module access tray
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
DE102004063927A1 (de) *	2004-01-23	2005-12-15	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
2003
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 PL PL03374874A patent/PL374874A1/pl unknown
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown

Also Published As

Publication number	Publication date
DE10234192B4 (de)	2009-11-26
CA2710100A1 (en)	2004-02-12
EP2191838A1 (de)	2010-06-02
EA009463B1 (ru)	2007-12-28
US20100247450A1 (en)	2010-09-30
US20050272634A1 (en)	2005-12-08
IL204577A (en)	2012-08-30
PL395151A1 (pl)	2011-08-16
HRP20070189A2 (en)	2007-07-31
EA013966B1 (ru)	2010-08-30
ES2285195T3 (es)	2007-11-16
HK1108625A1 (zh)	2008-05-16
IS8909A (is)	2010-07-02
EP1779862A1 (de)	2007-05-02
ZA200500726B (en)	2006-06-28
PL374874A1 (pl)	2005-11-14
ES2345673T3 (es)	2010-09-29
SI1526867T1 (sl)	2007-10-31
DK1779862T3 (da)	2010-08-16
JP4727988B2 (ja)	2011-07-20
US20100247452A1 (en)	2010-09-30
EP1779862B1 (de)	2010-05-19
CY1108052T1 (el)	2013-09-04
EA200700196A1 (ru)	2007-04-27
IS7633A (is)	2005-01-06
AU2003255290A1 (en)	2004-02-23
EP1526867A2 (de)	2005-05-04
WO2004012759A2 (de)	2004-02-12
DE10234192A1 (de)	2004-02-12
CN101099860A (zh)	2008-01-09
CA2493598A1 (en)	2004-02-12
UA85997C2 (en)	2009-03-25
MXPA05001120A (es)	2005-08-03
SI1779862T1 (sl)	2010-09-30
SG177004A1 (en)	2012-01-30
WO2004012759A3 (de)	2004-06-03
JP2006503001A (ja)	2006-01-26
EA200500281A1 (ru)	2005-06-30
AU2003255290B2 (en)	2009-04-09
JP2010280672A (ja)	2010-12-16
IS2671B (is)	2010-09-15
AU2009200748A1 (en)	2009-03-19
CN101099731B (zh)	2011-02-16
WO2004012759B1 (de)	2004-07-08
CY1110713T1 (el)	2015-06-10
ATE360436T1 (de)	2007-05-15
JP2010280670A (ja)	2010-12-16
HRP20050065A2 (en)	2005-10-31
CN101099860B (zh)	2011-06-01
HK1081841A1 (en)	2006-05-26
EP1526867B1 (de)	2007-04-25
DE50307140D1 (en)	2007-06-06
US20100247451A1 (en)	2010-09-30
US7745387B2 (en)	2010-06-29
KR20100077033A (ko)	2010-07-06
JP2010280671A (ja)	2010-12-16
KR20050026513A (ko)	2005-03-15
CN1681526A (zh)	2005-10-12
DK1526867T3 (da)	2007-09-17
HRP20100187A2 (hr)	2010-08-31
PT1779862E (pt)	2010-08-18
ATE468132T1 (de)	2010-06-15
UA94913C2 (ru)	2011-06-25
CN101099731A (zh)	2008-01-09
NO20051002L (no)	2005-04-18
EA200801236A1 (ru)	2009-02-27
PT1526867E (pt)	2007-07-09
IS8817A (is)	2009-05-06
BR0312981A (pt)	2005-06-14
DE50312729D1 (de)	2010-07-01

Legal Events

Date	Code	Title	Description
2011-02-28	FF	Patent granted
2014-03-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
DE50307140D1 (en)	2007-06-06	Erythropoietin in subpolycythämischen dosen
Mirhoseini et al.	1983	Myocardial revascularization by laser: a clinical report
Yu et al.	1997	Effects of photostimulation on wound healing in diabetic mice
EP2233150A3 (de)	2013-01-09	Erythropoietin zur Anwendung bei der Behandlung von Wunden oder der Transplantation von Zellen
ATE88191T1 (de)	1993-04-15	Polypeptide mit kollagen typ iv aktivitaet.
CA2467797A1 (en)	2004-11-20	Increased biocompatibility of implantable medical devices
US20080125622A1 (en)	2008-05-29	Cardiac wall tension relief with cell loss management
UA84665C2 (ru)	2008-11-25	Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы
WO2003057820A3 (en)	2003-12-04	Peptide activators of vegf
CA2073453A1 (en)	1991-07-13	Methods of enhancing wound healing and tissue repair
SI1567171T1 (sl)	2007-08-31	Uporaba dekstran sulfata za zdravljenje IBMIR
Ko et al.	1997	Durability of prefabricated versus normal random flaps against a bacterial challenge
Kimura et al.	2004	Coronary artery bypass grafting and aortic valve replacement in a patient with a tracheostoma
Lozano et al.	1976	A comparative study of the early vascularization of porous carbon and bone as a graft
Yamaguchi et al.	2005	Skin grafting: surgical techniques
Senges et al.	1983	Effect of brief periods of paced ventricular tachycardia on coronary blood flow in dogs before and after graded coronary stenosis
Guelinckx et al.	1986	Free muscle transplants for chronic infection of the fronto-cranial region
Moritz et al.	1992	Improved endothelialization of postfixation treated biological vascular grafts
Howes	1985	The latest wrinkles in wound healing
Laing et al.	1983	Skin replacement after burn injury
Bocchi et al.	1995	Pathological scar formation in burns: new biochemical and molecular factors in the healing process
Sanchez	1990	Cultivo in vitro de epidermis.
JPS6442441A (en)	1989-02-14	Macrophage activator
RU93037867A (ru)	1996-03-20	Способ лечения длительно незаживающих ран и трофических язв кожных покровов